| Literature DB >> 25196934 |
Tanja Grkovic1, Johanna S Blees2, Magdalena M Bayer3, Nancy H Colburn4, Cheryl L Thomas5, Curtis J Henrich6, Megan L Peach7, James B McMahon8, Tobias Schmid3, Kirk R Gustafson9.
Abstract
A cell-based high-throughput screen that assessed the cellular stability of a tumor suppressor protein PDCD4 (Programmed cell death 4) was used to identify a new guanidine-containing marine alkaloid mirabilin K (3), as well as the known compounds mirabilin G (1) and netamine M (2). The structures of these tricyclic guanidine alkaloids were established from extensive spectroscopic analyses. Compounds 1 and 2 inhibited cellular degradation of PDCD4 with EC50 values of 1.8 μg/mL and 2.8 μg/mL, respectively. Mirabilin G (1) and netamine M (2) are the first marine natural products reported to stabilize PDCD4 under tumor promoting conditions.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25196934 PMCID: PMC4145332 DOI: 10.3390/md12084593
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of the tricyclic guanidine alkaloids mirabilin G (1), netamine M (2), and mirabilin K (3).
NMR data for mirabilin K (3) trifluoroacetate salt in CDCl3.
| Position | δC a, Type | δH, Mult. ( | HMBC c | ROESY |
|---|---|---|---|---|
| 1- | 7.71, br s | |||
| 2 | 154.0, C | |||
| C2- | 7.00, br s | |||
| 3- | 7.05, br s | |||
| 4 | 52.9, CH | 3.80, br t (3.9) | 2, 6, 7 | 5b, 7, 12 |
| 5a | 32.9, CH2 | 1.89, m | 4, 7, 12 | |
| 5b | 1.64, m | 4, 7, 12 | 4 | |
| 6a | 29.6, CH2 | 1.99, m | 4, 5, 12 | |
| 6b | 1.43, m | 4, 5, 12 | ||
| 7 | 34.6, CH | 2.05, m | 4,6,12 | 4, 8a, 9 |
| 8a | 37.2, CH2 | 1.84, ddd (13.5, 5.0, 5.0) | 7, 9, 9Me, 12 | 7, 8b, 9 |
| 8b | 1.10, ddd (13.5, 12.6, 12.6) | 6, 9, 9Me, 12 | 8a | |
| 9 | 30.0, CH | 2.50, m | 8, 10, 11, 1′ | 7 |
| 9-Me | 22.4, CH3 | 1.06 3H, d (6.8) | 8, 9, 10 | 8a |
| 10 | 138.1, C | |||
| 11 | 54.9, CH | 3.98, d (6.3) | 7, 9, 10, 12, 1′ | 1′, 12 |
| 12 | 39.6, CH | 2.31, m | 4, 7, 8, 11 | 4, 11 |
| 1′ | 132.2, CH | 5.42, br t (7.1) | 9, 11, 3′ | 11, 2′, 3′ |
| 2′ | 27.8 CH2 | 2.02, m | 1, 10, 3′ | |
| 3′ | 29.6, CH2 | 1.24, m | 4′, 5′ | |
| 4′ | 31.5, CH2 | 1.26, m | 3′, 5′ | |
| 5′ | 22.5, CH2 | 1.28, m | 6′, 4′ | |
| 6′ | 14.0, CH3 | 0.88, t (6.8) | 4′, 5′ |
a Recorded at 150 MHz; b Recorded at 600 MHz; c Optimized for 8.3 Hz, correlations are from the proton(s) stated to the indicated carbon.
Figure 2Chem3D minimized core structure of mirabilin K (3) showing crucial ROESY correlations used to assign the relative configuration (4S*,7S*,9R*,11S*12R*).
Biological activities of compounds 1–3.
| Compound | PDCD4 EC50 a (μg/mL) | PDCD4 EC90 a (μg/mL) | Cytotoxicity b (μg/mL) |
|---|---|---|---|
| 1.8 | - | 4.2 | |
| 2.8 | 5.5 | 17.0 | |
| n.a. c | - | 10.6 | |
| Rapamycin d | 0.02 | 0.1 | >1.0 |
a EC50 and EC90 values represent the minimum concentration required for 50% and 90% recovery of the PDCD4-luciferase signal from TPA-induced degradation; b Values presented as the minimum concentration required for total luciferase signal loss, relative to TPA treated control cells; c Not active; d Positive control, concentration in μM.